GlassScriptPhysician profile
Anthony Gilbert Uribes
NPI 1720084791
$6,849.12
in general payments reported to CMS, 2019-2025
35 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $1,051 · 2021: $1,017 · 2022: $1,174 · 2023: $912 · 2024: $899 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,391.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $930.32 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $671.68 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $509.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $433.33 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $352.05 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.88 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $318.01 | 2019-2024 | |
| Lilly USA, LLC | $219.56 | 2020-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $201.00 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $168.54 | 2020-2022 | |
| Allergan, INC. | $138.10 | 2019-2020 | |
| Amgen INC. | $137.46 | 2019-2024 | Otezla, Repatha, Prolia |
| Sanofi-Aventis U.S. LLC | $136.65 | 2019-2023 | |
| Exact Sciences Corporation | $115.48 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $93.86 | 2019-2022 | |
| Daiichi Sankyo INC. | $83.14 | 2020-2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $65.99 | 2022 | |
| Abbott Laboratories | $60.04 | 2021-2022 | |
| Esperion Therapeutics, INC. | $56.94 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $51.98 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.99 | 2019-2021 | |
| Mylan Specialty L.P. | $37.78 | 2021 | |
| Corium, LLC | $33.58 | 2023 | Azstarys |
| Exeltis, USA INC. | $31.41 | 2022 | |
| Dexcom, INC. | $31.39 | 2022 | |
| Strongbridge US INC. | $26.26 | 2019 | |
| Organon LLC | $20.50 | 2025 | Jada System |
| Ironshore Pharmaceuticals INC. | $15.08 | 2019 | |
| Circassia INC. | $14.40 | 2019 | |
| Astellas Pharma US INC | $13.77 | 2019 | |
| Almatica Pharma LLC | $12.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.33 | 2020 | |
| Bioventus LLC | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Uribes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.